Barinthus Biotherapeutics (STU:2AB) LT-Debt-to-Total-Asset: 0.10 (As of Mar. 2026)

What is Barinthus Biotherapeutics LT-Debt-to-Total-Asset?

Barinthus Biotherapeutics STU:2AB -0.88% 14 LT-Debt-to-Total-Asset is 0.10 as of Mar. 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.96. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Barinthus Biotherapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.10.

Barinthus Biotherapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.07) to Mar. 2026 (0.10). It may suggest that Barinthus Biotherapeutics is progressively becoming more dependent on debt to grow their business.

Barinthus Biotherapeutics (STU:2AB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Barinthus Biotherapeutics LT-Debt-to-Total-Asset Related Terms

Barinthus Biotherapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics LT-Debt-to-Total-Asset Chart

Barinthus Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.03

0.05

0.06

0.09

Barinthus Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.08	0.09	0.09	0.10

14GF Score

Barinthus Biotherapeutics PLC STU:2AB

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Barinthus Biotherapeutics LT-Debt-to-Total-Asset Calculation

Barinthus Biotherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	7.906	/	83.836
	=

Barinthus Biotherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	7.788	/	79.704
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.10 mean?

Barinthus Biotherapeutics (STU:2AB) has a LT-Debt-to-Total-Asset of 0.10 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Barinthus Biotherapeutics and its competitors.

Is Barinthus Biotherapeutics' LT-Debt-to-Total-Asset too high?

Barinthus Biotherapeutics' current LT-Debt-to-Total-Asset is 0.10. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.

How does Barinthus Biotherapeutics' LT-Debt-to-Total-Asset compare to VTGN and PSTV?

Barinthus Biotherapeutics' LT-Debt-to-Total-Asset of 0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current LT-Debt-to-Total-Asset is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Barinthus Biotherapeutics stock overvalued right now?

Barinthus Biotherapeutics (STU:2AB) has a current LT-Debt-to-Total-Asset of 0.10. The stock's GF Value™ is €0.96, compared to a current price of €0.57 — trading 41.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.10. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current LT-Debt-to-Total-Asset is 0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.57 is trading 41.1% below its estimated GF Value™ of €0.96.

Key valuation signals for STU:2AB:

LT-Debt-to-Total-Asset: 0.10
GF Value™: €0.96 vs. price of €0.57 (41.1% below fair value)
GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies VTGN PSTV PVCT KYNB TVGN GRDX DYAI NRSN SER LITS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges BRNS:USA

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874

Website https://www.barinthusbio.com

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

14GF Score

Get the complete analysis for STU:2AB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.57

Price

€0.96

GF Value

View STU:2AB Analysis

See LT-Debt-to-Total-Asset data for all stocks →